FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百奧賽圖(北京)醫藥科技股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02315 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 110,781,920 | RMB | | 1 RMB | | 110,781,920 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 110,781,920 | RMB | | 1 RMB | | 110,781,920 | | 2. 股份分類 | 普通股 | 股份 ...

Core Viewpoint - The company BaiO Saite-B (02315) has seen its stock price increase by over 10%, with a current price of 45.56 HKD, driven by a strong earnings forecast for 2025, projecting a net profit increase of up to 4.4 times compared to the previous year [1] Group 1: Financial Performance - BaiO Saite-B forecasts a net profit of 162 million to 182 million HKD for 2025, representing a year-on-year increase of 384.26% to 443.88% [1] - The company's revenue growth is attributed to the ongoing expansion in overseas markets and the recovery of the domestic biopharmaceutical industry [1] Group 2: Business Strategy and Partnerships - The company has established multiple significant licensing agreements with leading domestic and international pharmaceutical companies since 2025 [1] - Notable partnerships include a global licensing agreement with BeiGene for antibody molecules and an agreement with Merck for the development of antibody-conjugated LNPs [1]

Core Viewpoint - The company BaiO Saite-B (02315) has seen a significant stock price increase, with a recent rise of over 10%, attributed to its strong earnings forecast for 2025, projecting a net profit increase of 384.26% to 443.88% year-on-year [1] Group 1: Financial Performance - BaiO Saite-B forecasts a net profit for 2025 between 162 million to 182 million yuan, indicating substantial growth compared to previous years [1] - The company attributes its revenue growth to the ongoing expansion in overseas markets and the recovery of the domestic biopharmaceutical industry [1] Group 2: Operational Efficiency - High technical barriers have allowed the company to maintain elevated gross margins, while lean management initiatives have further enhanced operational efficiency [1] - The rapid improvement in profitability is a result of these operational enhancements [1] Group 3: Strategic Partnerships - Since 2025, the company has established external licensing agreements with several leading domestic and international pharmaceutical companies, which are expected to contribute to revenue through milestone payments [1] - Notable partnerships include a global licensing agreement with BeiGene for antibody molecules and an agreement with Merck for the development of antibody-drug conjugates using the RenMice platform [1]

Core Viewpoint - Baosai Technology-B (02315) has seen a significant stock price increase, with a recent rise of over 10%, attributed to strong earnings forecasts and strategic partnerships in the biopharmaceutical sector [1] Group 1: Earnings Forecast - The company has projected a net profit attributable to shareholders for 2025 between 162 million to 182 million yuan, representing a year-on-year increase of 384.26% to 443.88% [1] - The growth is driven by the continuous expansion in overseas markets and a recovery in the domestic biopharmaceutical industry, leading to rapid revenue growth [1] Group 2: Operational Efficiency - High technical barriers have ensured that the company's gross profit margin remains elevated, while lean management initiatives have further enhanced operational efficiency [1] - The company's profitability has improved rapidly as a result of these factors [1] Group 3: Strategic Partnerships - Since 2025, the company has established external licensing agreements with several leading domestic and international pharmaceutical companies, which are expected to contribute to revenue through milestone payments [1] - Notable partnerships include a global licensing agreement with BeiGene for antibody molecules and an agreement with Merck for the development of antibody-conjugated LNPs using the RenMice platform [1]

Group 1 - The companies with the largest increase in Hong Kong Stock Connect holdings are Shandong Molong (+2.80%), Junda Co. (+2.32%), and Beijing Jingcheng Machinery Electric (+1.51%) [1][2] - The companies with the largest decrease in Hong Kong Stock Connect holdings are Southern Hang Seng Technology (-2.27%), Yingfu Fund (-1.75%), and Hang Seng China Enterprises (-1.53%) [1][2] - Over the last five trading days, Junda Co. (+12.94%), Nanhua Futures (+9.45%), and Shandong Molong (+3.83%) saw the largest increases in holdings [1][3] Group 2 - The latest day increase in holdings for Shandong Molong is 61.06%, Junda Co. is 62.00%, and Beijing Jingcheng Machinery Electric is 45.18% [2] - The latest day decrease in holdings for Southern Hang Seng Technology is 64.22%, Yingfu Fund is 0.91%, and Hang Seng China Enterprises is 0.76% [2] - Over the last 20 days, Junda Co. has increased by 31.74%, Baiaosaitu-B by 12.93%, and Zhongwei New Materials by 11.57% [4]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook with expected stock price appreciation of over 15% relative to the benchmark index [2][11]. Core Insights - The company is projected to achieve significant revenue growth driven by its core business and antibody platform, with expected revenues of RMB 1.376 billion in 2025, representing a year-on-year growth of 40.4% [2][8]. - The net profit attributable to shareholders is forecasted to reach RMB 167 million in 2025, reflecting a staggering growth rate of 399.3% compared to the previous year [2][8]. - The company has made substantial advancements in its animal model and preclinical CRO business, which are key drivers of revenue growth, particularly in the first half of 2025 [8]. Financial Forecasts - Revenue projections for 2024, 2025, 2026, and 2027 are RMB 980 million, RMB 1.376 billion, RMB 1.845 billion, and RMB 2.416 billion, respectively, with growth rates of 36.8%, 40.4%, 34.1%, and 31.0% [2][9]. - The net profit attributable to shareholders is expected to grow from RMB 34 million in 2024 to RMB 530 million in 2027, with corresponding growth rates of 108.8%, 399.3%, 93.3%, and 63.6% [2][9]. - Earnings per share (EPS) are projected to increase from RMB 0.08 in 2024 to RMB 1.19 in 2027, indicating strong profitability growth [2][9]. Business Developments - The company has successfully expanded its humanized mouse model offerings, launching over 400 new models in 2025, which enhances its technological barriers and supports its goal of becoming a global hub for new drug development [8]. - Strategic partnerships have been established with leading pharmaceutical companies, including a global licensing agreement with BeiGene and an antibody licensing deal with Merck, which are expected to contribute to long-term revenue growth [8].

Core Viewpoint - The company Baidu Biotechnology (02315) has announced a positive earnings forecast for the fiscal year 2025, leading to a significant increase in its stock price by nearly 13% following the announcement [1] Financial Performance - The company expects to achieve revenue of approximately 1.369 billion to 1.389 billion yuan, representing an increase of 389 million to 408 million yuan compared to the previous year, with a year-on-year growth rate of 39.61% to 41.65% [1] - The anticipated net profit attributable to shareholders is projected to be around 162 million to 182 million yuan, which is an increase of 129 million to 149 million yuan from the previous year, indicating a substantial year-on-year growth of 384.26% to 443.88% [1] Market Dynamics - The company's revenue growth is attributed to the continuous expansion in overseas markets, coupled with a recovery in the domestic biopharmaceutical industry [1] - The high barriers to entry in technology have helped maintain high gross margins, while lean management initiatives have further enhanced operational efficiency, leading to a rapid increase in profitability [1]

（原标题：港股异动 | 百奥赛图-B(02315)盈喜后涨近13% 预计全年营收增长约40% 纯利增长约400%） 智通财经APP获悉，百奥赛图-B(02315)盈喜后涨近13%，截至发稿，涨8.82%，报47.88港元，成交额 2771.5万港元。 公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增 长；高壁垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运营效率提升，公司盈利水 平得以快速提高。 消息面上，百奥赛图发布2025年度业绩预告，预计全年实现营收约13.69亿元-13.89亿元，较上年同期增 加3.89亿元至4.08亿元，同比增幅为39.61%到41.65%；预计实现归母净利润约为1.62亿元-1.82亿元，较 上年同期增加1.29亿元至1.49亿元，同比大幅增长384.26%至443.88%。 ...

公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增 长；高壁垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运营效率提升，公司盈利水 平得以快速提高。 百奥赛图-B(02315)盈喜后涨近13%，截至发稿，涨8.82%，报47.88港元，成交额2771.5万港元。 消息面上，百奥赛图发布2025年度业绩预告，预计全年实现营收约13.69亿元-13.89亿元，较上年同期增 加3.89亿元至4.08亿元，同比增幅为39.61%到41.65%；预计实现归母净利润约为1.62亿元-1.82亿元，较 上年同期增加1.29亿元至1.49亿元，同比大幅增长384.26%至443.88%。 ...

Core Insights - The report highlights significant changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Companies with Increased Holdings - Nanhua Futures (02691) saw the largest increase in holdings, up by 4.45% to a total of 10.44% [2]. - Junshi Biosciences (01877) experienced a 2.39% increase, bringing its total holding to 55.84% [2]. - Lion Group (02562) had a 2.21% increase, resulting in a holding of 53.31% [2]. - Other notable increases include Haotian International Investment (01341) at +1.61% (67.02%) and Junda Co., Ltd. (02865) at +1.43% (59.68%) [2]. Group 2: Companies with Decreased Holdings - Yihua Tong (02402) reported the largest decrease, down by 2.06% to 28.06% [2]. - Shandong Molong (00568) saw a reduction of 1.99%, with a current holding of 58.26% [2]. - Jihong Co., Ltd. (02603) decreased by 1.27%, now holding 57.37% [2]. - Other significant decreases include China Merchants Hengsheng Technology (03423) at -0.85% (3.15%) and CIFI Holdings Group (00884) at -0.82% (9.03%) [2]. Group 3: Five-Day Changes in Holdings - Junda Co., Ltd. (02865) had the highest five-day increase at +12.13%, reaching 59.68% [3]. - Nanhua Futures (02691) increased by 9.08% to 10.44% [3]. - Other notable increases include Baidu Biotechnology-B (02315) at +3.13% (22.65%) and Junshi Biosciences (01877) at +2.77% (55.84%) [3]. Group 4: Twenty-Day Changes in Holdings - Junda Co., Ltd. (02865) also led the twenty-day increase with +27.85%, holding 59.68% [4]. - Baidu Biotechnology-B (02315) increased by +14.85% to 22.65% [4]. - Other significant increases include Zhongwei New Materials (02579) at +11.72% (16.27%) and Youjia Innovation (02431) at +8.62% (14.46%) [4].